cyclizine and ziprasidone both increase sedation. Use Caution/Monitor.cyclobenzaprineMonitor Closely (4)cyclobenzaprine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. cyclobenzaprine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor. ziprasidone increases effects of cyclobenzaprine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. cyclobenzaprine and ziprasidone both increase sedation. Use Caution/Monitor.cyclosporineMinor (1)cyclosporine will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.cyproheptadineMonitor Closely (1)cyproheptadine and ziprasidone both increase sedation. Use Caution/Monitor.dabrafenibMonitor Closely (1)dabrafenib and ziprasidone both increase QTc interval. Use Caution/Monitor.dantroleneMonitor Closely (1)dantrolene and ziprasidone both increase sedation. Use Caution/Monitor.daridorexantMonitor Closely (1)ziprasidone and daridorexant both increase sedation. Modify Therapy/Monitor Closely. Coadministration increases risk of CNS depression, which can lead to additive impairment of psychomotor performance and cause daytime impairment. darifenacinMonitor Closely (3)darifenacin decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. darifenacin decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor. ziprasidone increases effects of darifenacin by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.Minor (1)darifenacin will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.darunavirMinor (1)darunavir will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dasatinibMonitor Closely (1)dasatinib and ziprasidone both increase QTc interval. Modify Therapy/Monitor Closely.Minor (1)dasatinib will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.degarelixSerious - Use Alternative (1)degarelix and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.desfluraneMonitor Closely (1)desflurane and ziprasidone both increase QTc interval. Use Caution/Monitor.desipramineMonitor Closely (1)ziprasidone and desipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)desipramine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.deutetrabenazineMonitor Closely (3)ziprasidone and deutetrabenazine both increase sedation. Use Caution/Monitor. ziprasidone and deutetrabenazine both increase QTc interval. Use Caution/Monitor. At the maximum recommended dose, deutetrabenazine does not prolong QT interval to a clinically relevant extent. Certain circumstances may increase risk of torsade de pointes and/or sudden death in association with drugs that prolong the QTc interval (eg, bradycardia, hypokalemia or hypomagnesemia, coadministration with other drugs that prolong QTc interval, presence of congenital QT prolongation). ziprasidone and deutetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. The risk for parkinsonism, neuroleptic malignant syndrome, and akathisia may be increased by concomitant use of deutetrabenazine and dopamine antagonists or antipsychotics.dexamethasoneMinor (1)dexamethasone will decrease the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.dexchlorpheniramineMonitor Closely (1)dexchlorpheniramine and ziprasidone both increase sedation. Use Caution/Monitor.dexfenfluramineMonitor Closely (1)ziprasidone increases and dexfenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dexmedetomidineMonitor Closely (1)dexmedetomidine and ziprasidone both increase sedation. Use Caution/Monitor.dexmethylphenidateMonitor Closely (1)ziprasidone increases and dexmethylphenidate decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetamineMonitor Closely (1)ziprasidone increases and dextroamphetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dextroamphetamine transdermalMonitor Closely (1)ziprasidone, dextroamphetamine transdermal. Either increases effects of the other by serotonin levels. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor for signs and symptoms of serotonin syndrome, particularly during initiation or dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and concomitant serotonergic drug(s).dextromethorphanMonitor Closely (1)dextromethorphan, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dextromoramideMonitor Closely (1)dextromoramide and ziprasidone both increase sedation. Use Caution/Monitor.DHEA, herbalMinor (1)DHEA, herbal will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.diamorphineMonitor Closely (1)diamorphine and ziprasidone both increase sedation. Use Caution/Monitor.diazepamMonitor Closely (1)diazepam and ziprasidone both increase sedation. Use Caution/Monitor.dichlorphenamideMonitor Closely (1)dichlorphenamide and ziprasidone both decrease serum potassium. Use Caution/Monitor.dicyclomineMonitor Closely (3)dicyclomine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. dicyclomine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor. ziprasidone increases effects of dicyclomine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.diethylpropionMonitor Closely (1)ziprasidone increases and diethylpropion decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.difelikefalinMonitor Closely (1)difelikefalin and ziprasidone both increase sedation. Use Caution/Monitor.difenoxin hclMonitor Closely (1)difenoxin hcl and ziprasidone both increase sedation. Use Caution/Monitor.dihydroergotamineMonitor Closely (1)dihydroergotamine, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).dimenhydrinateMonitor Closely (1)dimenhydrinate and ziprasidone both increase sedation. Use Caution/Monitor.diphenhydramineMonitor Closely (4)diphenhydramine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. diphenhydramine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor. ziprasidone increases effects of diphenhydramine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia. diphenhydramine and ziprasidone both increase sedation. Use Caution/Monitor.diphenoxylate hclMonitor Closely (1)diphenoxylate hcl and ziprasidone both increase sedation. Use Caution/Monitor.dipipanoneMonitor Closely (1)dipipanone and ziprasidone both increase sedation. Use Caution/Monitor.disopyramideContraindicated (1)disopyramide and ziprasidone both increase QTc interval. Contraindicated.dobutamineMonitor Closely (1)ziprasidone increases and dobutamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dofetilideSerious - Use Alternative (1)dofetilide and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.dolasetronMonitor Closely (1)dolasetron and ziprasidone both increase QTc interval. Modify Therapy/Monitor Closely.donepezilSerious - Use Alternative (1)donepezil and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.dopamineMonitor Closely (1)ziprasidone increases and dopamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)ziprasidone decreases effects of dopamine by pharmacodynamic antagonism. Contraindicated.dopexamineMonitor Closely (1)ziprasidone increases and dopexamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.dosulepinMonitor Closely (1)ziprasidone and dosulepin both increase sedation. Use Caution/Monitor.doxepinMonitor Closely (1)ziprasidone and doxepin both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)doxepin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.doxylamineMonitor Closely (1)doxylamine and ziprasidone both increase sedation. Use Caution/Monitor.dronedaroneSerious - Use Alternative (2)dronedarone and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. dronedarone will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated.droperidolMonitor Closely (2)droperidol and ziprasidone both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. droperidol and ziprasidone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)droperidol and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.efavirenzSerious - Use Alternative (1)efavirenz and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.Minor (1)efavirenz will decrease the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.eletriptanMonitor Closely (1)eletriptan, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).eliglustatSerious - Use Alternative (1)eliglustat and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.encorafenibSerious - Use Alternative (1)encorafenib and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. Encorafenib is associated with dose-dependent QTc interval prolongation. Avoid with drugs known to prolong QT interval.entrectinibSerious - Use Alternative (1)ziprasidone and entrectinib both increase QTc interval. Avoid or Use Alternate Drug.ephedrineMonitor Closely (1)ziprasidone increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.epinephrineMonitor Closely (1)ziprasidone increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)epinephrine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.epinephrine racemicMonitor Closely (1)ziprasidone increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)epinephrine racemic and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.ergoloid mesylatesMonitor Closely (1)ergoloid mesylates, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).ergotamineMonitor Closely (1)ergotamine, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).eribulinSerious - Use Alternative (1)eribulin and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. Potential for enhanced QTc-prolonging effects; if concurrent use is necessary then ECG monitoring is recommended.erythromycin baseMonitor Closely (1)erythromycin base will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)erythromycin base and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinateMonitor Closely (1)erythromycin ethylsuccinate will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)erythromycin ethylsuccinate and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.erythromycin lactobionateMonitor Closely (1)erythromycin lactobionate will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)erythromycin lactobionate and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearateMonitor Closely (1)erythromycin stearate will increase the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.Serious - Use Alternative (1)erythromycin stearate and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.escitalopramContraindicated (2)escitalopram and ziprasidone both increase QTc interval. Contraindicated. ziprasidone and escitalopram both increase QTc interval. Contraindicated.esketamine intranasalMonitor Closely (1)esketamine intranasal, ziprasidone. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.eslicarbazepine acetateMinor (1)eslicarbazepine acetate will decrease the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.estazolamMonitor Closely (1)estazolam and ziprasidone both increase sedation. Use Caution/Monitor.ethanolMonitor Closely (1)ziprasidone and ethanol both increase sedation. Use Caution/Monitor.Minor (1)ethanol, ziprasidone. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression.etomidateMonitor Closely (1)etomidate and ziprasidone both increase sedation. Use Caution/Monitor.etravirineMinor (1)etravirine will decrease the level or effect of ziprasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.eucalyptusMinor (1)ziprasidone and eucalyptus both increase sedation. Minor/Significance Unknown.exenatide injectable solutionMonitor Closely (1)ziprasidone, exenatide injectable solution. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.exenatide injectable suspensionMonitor Closely (1)ziprasidone, exenatide injectable suspension. Other (see comment). Use Caution/Monitor. Comment: Atypical antipsychotics have been associated with hyperglycemia that may alter blood glucose control; monitor glucose levels closely.ezogabineMonitor Closely (1)ezogabine, ziprasidone. Either increases toxicity of the other by QTc interval. Use Caution/Monitor. Slight and transient QT-prolongation observed with ezogabine, particularly when dose titrated to 1200 mg/day. QT interval should be monitored when ezogabine is prescribed with agents known to increase QT interval.fenfluramineMonitor Closely (2)ziprasidone decreases effects of fenfluramine by pharmacodynamic antagonism. Use Caution/Monitor. Potent serotonin receptor antagonists may decrease fenfluramine efficacy. If coadministered, monitor appropriately. ziprasidone increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.fentanylMonitor Closely (1)fentanyl, ziprasidone. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).fesoterodineMonitor Closely (3)fesoterodine decreases levels of ziprasidone by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. fesoterodine decreases levels of ziprasidone by pharmacodynamic antagonism. Use Caution/Monitor. ziprasidone increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.fexinidazoleSerious - Use Alternative (1)fexinidazole and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval.finerenoneMonitor Closely (1)ziprasidone will increase the